Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus

Lupus

Volumn 25, Issue 1, 2016, Pages 18-27

  Mikolajczyk T P ^a   Osmenda, G ^a   Batko, B ^b   Wilk, G ^a   Krezelok, M ^b   Skiba, D ^a,c   Sliwa, T ^a   Pryjma, J R ^d   Guzik, T J ^a,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b J Dietl Hospital   (Poland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

flow mediated dilation; Intima media thickness; monocyte subsets; SLE

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; GLYCERYL TRINITRATE; BIOLOGICAL MARKER; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY; CELL HETEROGENEITY; CELL SUBPOPULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ASYMPTOMATIC DISEASE; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMPLICATION; FLOW CYTOMETRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD14; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BIOMARKERS; BRACHIAL ARTERY; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTORS, IGG; RISK FACTORS; VASODILATION; YOUNG ADULT;

EID: 84951299770     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315598014     Document Type: Article

References (48)

1. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-706.
2. Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013; 166: 622-628.e621.
3. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
4. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
5. Wilk G, Osmenda G, Matusik P, et al. Endothelial function assessment in atherosclerosis: Comparison of brachial artery flow-mediated vasodilation and peripheral arterial tonometry. Pol Arch Med Wewn 2013; 123: 443-452.
6. Telles RW, Lanna CC, Sousa AJ, et al. Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol 2013; 32: 1293-1300.
7. Ammirati E, Bozzolo EP, Contri R, et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis 2014; 24: 751-759.
8. Gustafsson JT, Svenungsson E,. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014; 47: 67-76.
9. McMahon M, Skaggs BJ, Sahakian L, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011; 70: 1619-1624.
10. Tenedios F, Erkan D, Lockshin MD,. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14: 691-696.
11. Cojocaru IM, Cojocaru M, Butnaru L, Miu G, Tanasescu R,. Study of anti-endothelial cell antibodies in SLE patients with acute ischemic stroke. Rom J Intern Med 2010; 48: 173-177.
12. Steinbach F, Henke F, Krause B, Thiele B, Burmester GR, Hiepe F,. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis 2000; 59: 283-288.
13. Wong KL, Tai JJ, Wong WC, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118: e16-e31.
14. Heine GH, Ulrich C, Seibert E, et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73: 622-629.
15. Shantsila E, Tapp LD, Wrigley BJ, et al. Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis 2014; 234: 4-10.
16. Schlitt A, Heine GH, Blankenberg S, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004; 92: 419-424.
17. Shantsila E, Lip GY,. Monocyte diversity in myocardial infarction. J Am Coll Cardiol 2009; 54: 139-142.
18. Frantz S, Hofmann U, Fraccarollo D, et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J 2013; 27: 871-881.
19. van der Laan AM, Hirsch A, Robbers LF, et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: Monocytes and myocardial infarction. Am Heart J 2012; 163: 57-65.e52.
20. Surdacki A, Sulicka J, Korkosz M, et al. Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis. J Rheumatol 2014; 41: 481-489.
21. Mikołajczyk TP, Skiba D, Batko B, et al. Characterization of the impairment of the uptake of apoptotic polymorphonuclear cells by monocyte subpopulations in systemic lupus erythematosus. Lupus 2014; 23: 1358-1369.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
23. Sulicka J, Surdacki A, Mikołajczyk T, et al. Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology 2013; 218: 810-816.
24. Bartels CM, Buhr KA, Goldberg JW, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014; 41: 680-687.
25. Conti F, Spinelli FR, Alessandri C, et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: Focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 2014; 34: 661-668.
26. Matusik P, Guzik B, Weber C, Guzik TJ,. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice? Thromb Haemost 2012; 108: 443-456.
27. Kiss E, Soltesz P, Der H, et al. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006; 27: 211-217.
28. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH,. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292-297.
29. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
30. Inaba Y, Chen JA, Bergmann SR,. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imaging 2010; 26: 631-640.
31. Karadag O, Calguneri M, Atalar E, et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007; 26: 695-699.
32. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
33. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
34. Mikołajczyk TP, Skrzeczyńska-Moncznik JE, Zarebski MA, et al. Interaction of human peripheral blood monocytes with apoptotic polymorphonuclear cells. Immunology 2009; 128: 103-113.
35. Ziegler-Heitbrock L,. The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol 2007; 81: 584-592.
36. Franzeck FC, Hof D, Spescha RD, et al. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 2012; 220: 282-286.
37. Paneni F, Costantino S, Castello L, et al. Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: Insights in patients with diabetes. Eur Heart J 2015; 36: 817-828.
38. Rogacev KS, Ulrich C, Blömer L, et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376.
39. Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
40. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010; 212: 171-176.
41. Ulrich C, Heine GH, Gerhart MK, Köhler H, Girndt M,. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant 2008; 8: 103-110.
42. Rothe G, Herr AS, Stöhr J, Abletshauser C, Weidinger G, Schmitz G,. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999; 144: 251-261.
43. Mosig S, Rennert K, Krause S, et al. Different functions of monocyte subsets in familial hypercholesterolemia: Potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23: 866-874.
44. Ziegler-Heitbrock HW, Fingerle G, Ströbel M, et al. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993; 23: 2053-2058.
45. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HW,. Differential cytokine expression in human blood monocyte subpopulations: A polymerase chain reaction analysis. Blood 1996; 87: 373-377.
46. Yuan W, DiMartino SJ, Redecha PB, Ivashkiv LB, Salmon JE,. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum 2011; 63: 212-218.
47. Banai S, Finkelstein A, Almagor Y, et al. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. Am Heart J 2013; 165: 234-240.e231.
48. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199-207.e115.